CN105873440B - 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 - Google Patents

抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 Download PDF

Info

Publication number
CN105873440B
CN105873440B CN201380081931.2A CN201380081931A CN105873440B CN 105873440 B CN105873440 B CN 105873440B CN 201380081931 A CN201380081931 A CN 201380081931A CN 105873440 B CN105873440 B CN 105873440B
Authority
CN
China
Prior art keywords
composition
formulas
administration
another embodiment
tie2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380081931.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105873440A (zh
Inventor
D·L·弗林
M·D·考夫曼
B·史密斯
M·S·鲁道兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Priority to CN201810436668.9A priority Critical patent/CN108464981B/zh
Publication of CN105873440A publication Critical patent/CN105873440A/zh
Application granted granted Critical
Publication of CN105873440B publication Critical patent/CN105873440B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380081931.2A 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 Active CN105873440B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810436668.9A CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/069005 WO2015069266A1 (fr) 2013-11-07 2013-11-07 Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810436668.9A Division CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Publications (2)

Publication Number Publication Date
CN105873440A CN105873440A (zh) 2016-08-17
CN105873440B true CN105873440B (zh) 2018-06-01

Family

ID=53041876

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380081931.2A Active CN105873440B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
CN201810436668.9A Active CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810436668.9A Active CN108464981B (zh) 2013-11-07 2013-11-07 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Country Status (7)

Country Link
EP (1) EP3065549A4 (fr)
JP (1) JP6568093B2 (fr)
KR (2) KR20210063475A (fr)
CN (2) CN105873440B (fr)
AU (3) AU2013404949B2 (fr)
CA (1) CA2929715A1 (fr)
WO (1) WO2015069266A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108464981A (zh) * 2013-11-07 2018-08-31 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP3102605B1 (fr) 2014-02-04 2018-11-14 Pfizer Inc Association d'un antagoniste du pd-1 et d'un inhibiteur du vegfr pour traiter le cancer
SG11201706918YA (en) 2015-02-26 2017-09-28 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US20180106811A1 (en) * 2015-05-27 2018-04-19 Albert Einstein College Of Medicine, Inc. Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2017172734A1 (fr) 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Traitement de métastases cancéreuses
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
CA3049926A1 (fr) 2017-01-17 2018-07-26 Heparegenix Gmbh Inhibiteurs de proteine kinase pour favoriser la regeneration du foie, ou pour reduire ou prevenir la mort des hepatocytes
CN106822128A (zh) * 2017-02-24 2017-06-13 南华大学附属第医院 酪氨酸激酶抑制剂dcc‑2036的新应用
KR20200115607A (ko) 2018-01-31 2020-10-07 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
EP4013417A1 (fr) * 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Procédés et compositions pour traiter des malformations vasculaires
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
MX2022008097A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
CN115135308A (zh) 2019-12-30 2022-09-30 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
US9296722B2 (en) * 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
AU2012205601B2 (en) * 2011-01-11 2016-03-24 Novartis Ag Combination
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
WO2013036232A2 (fr) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives
WO2013043569A1 (fr) * 2011-09-20 2013-03-28 Vical Incorporated Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
WO2015069266A1 (fr) * 2013-11-07 2015-05-14 Flynn Daniel L Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.;Javier Cortes et al.;《Lancet》;20110303;第377卷(第9769期);914-923 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108464981A (zh) * 2013-11-07 2018-08-31 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
CN108464981B (zh) * 2013-11-07 2022-06-24 德西费拉制药有限责任公司 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途

Also Published As

Publication number Publication date
JP6568093B2 (ja) 2019-08-28
KR20210063475A (ko) 2021-06-01
CA2929715A1 (fr) 2015-05-14
JP2017500371A (ja) 2017-01-05
CN108464981B (zh) 2022-06-24
AU2013404949A1 (en) 2016-05-26
AU2021200113A1 (en) 2021-03-04
AU2013404949B2 (en) 2018-10-18
AU2019200261A1 (en) 2019-01-31
EP3065549A1 (fr) 2016-09-14
WO2015069266A1 (fr) 2015-05-14
CN105873440A (zh) 2016-08-17
KR20160070188A (ko) 2016-06-17
EP3065549A4 (fr) 2017-05-24
CN108464981A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
US20190091217A1 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
EP3903828A1 (fr) Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
CN104530413B (zh) 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN110418851A (zh) 癌症的治疗和诊断方法
WO2017013160A1 (fr) Composé 4-amino-6-(2,6-dichlorophényl)-8-méhyle-2-(phénylamino)-pyrido[2,3-d] pyrimidin-7(8h)-one pour le traitement des cancers solides
CN107949387A (zh) 用谷氨酰胺酶抑制剂治疗肺癌
CN105263484B (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途
BR112020024404A2 (pt) biomarcadores para determinar a eficácia de inibidores de checkpoint imunológico
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
US11224608B2 (en) Compounds and methods for treating cancer
CN108883147A (zh) 用于治疗异常Wnt信号传送的稳定化BCL9肽
US20160250220A1 (en) Treatment for pancreatic cancer
WO2019233469A1 (fr) Utilisation d'un inhibiteur de la voie de signalisation pdgfr pour la préparation d'un médicament destiné au traitement de maladies inflammatoires intestinales
CN109475558A (zh) 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
US20230277522A9 (en) Methods for treating vascular malformations
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
CN105998068A (zh) Egfr小分子不可逆抑制剂和t细胞联合在抗肿瘤治疗中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant